6.43
+0.32(+5.24%)
Currency In USD
| Previous Close | 6.11 |
| Open | 6.31 |
| Day High | 6.48 |
| Day Low | 6.13 |
| 52-Week High | 10.08 |
| 52-Week Low | 1.1 |
| Volume | 1.64M |
| Average Volume | 1.63M |
| Market Cap | 233.42M |
| PE | -3.38 |
| EPS | -1.9 |
| Moving Average 50 Days | 5.73 |
| Moving Average 200 Days | 2.99 |
| Change | 0.32 |
If you invested $1000 in Immuneering Corporation (IMRX) since IPO date, it would be worth $365.55 as of October 08, 2025 at a share price of $6.43. Whereas If you bought $1000 worth of Immuneering Corporation (IMRX) shares 3 years ago, it would be worth $472.79 as of October 08, 2025 at a share price of $6.43.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
GlobeNewswire Inc.
Sep 26, 2025 8:01 PM GMT
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on S
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
GlobeNewswire Inc.
Sep 25, 2025 4:08 AM GMT
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public offering of 18,959,914 shares of
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
GlobeNewswire Inc.
Sep 24, 2025 8:05 PM GMT
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a proposed underwritten public offering of shares of its Class A common